Cidara Therapeutics Shares Are Trading Higher After the Company Announced the Divestiture of Rezafungin to Mundipharma*, Reacquired Global Development and Commercial Rights to CD388 and Announced $240 Million in Private Placement Financing
Cidara Therapeutics宣佈將Rezafungin剝離給Mundipharma*，重新收購了 CD388 的全球開發和商業權，並宣佈了2.4億美元的私募融資，此後，Cidara Therapeutics的股價走高